KR900702045A - 천연 hiv gp 160의 제조방법 - Google Patents

천연 hiv gp 160의 제조방법

Info

Publication number
KR900702045A
KR900702045A KR1019900700768A KR900700768A KR900702045A KR 900702045 A KR900702045 A KR 900702045A KR 1019900700768 A KR1019900700768 A KR 1019900700768A KR 900700768 A KR900700768 A KR 900700768A KR 900702045 A KR900702045 A KR 900702045A
Authority
KR
South Korea
Prior art keywords
cell line
medium
serum
purified
free medium
Prior art date
Application number
KR1019900700768A
Other languages
English (en)
Inventor
지. 사른 가다란 망가라세릴
바디 에스. 카리아나라만 바니암
Original Assignee
에프. 지. 엠 헤르만스 에이. 지. 제이. 베르메렌
악조 엔. 브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 지. 엠 헤르만스 에이. 지. 제이. 베르메렌, 악조 엔. 브이. filed Critical 에프. 지. 엠 헤르만스 에이. 지. 제이. 베르메렌
Publication of KR900702045A publication Critical patent/KR900702045A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Element Separation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physical Vapour Deposition (AREA)

Abstract

내용 없음

Description

천연 HIV GP 160의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. HUT 78 셀라인으로 부터 얻은 세포를 HTLV-Ⅲ451로 감염시켜 6D5451셀라인(CRL 9946)을 제조하고, 상기 6D5451셀라인을 세포성장을 촉진하는 조건하에서 무혈청 배지내에서 배양하며, 상기 배지로 부터 천연 gp 160을 분리하는 것으로 구성된 천연 인체 면역 결핍증 비루스 gp 160의 제조방법.
  2. T-셀라인을 인체 면역 결핍증 비루스로 감염시키고, 세포 생장을 촉진하는 조건하에 배지중에서 이를 배양하여, 당단백질을 상기 배지내로 분비시키는 것으로 구성되는 상기 비루스로 부터 엔벨로프 단백질을 제조하는 방법에 있어서, 6D5451로 감염시킨 T-셀라인으로 부터 얻은 세포를 무혈청 배지내에서 배양하고, 이 배지로부터 천연 HIV엔벨로프 당단백질 gp 160에 상응하는 160kD 단백질을 분리하는 것을 특징으로 하는 엔벨로프 단백질의 제조방법.
  3. 무혈청 배지 중의 6D5451세포.
  4. 무혈청 배지중의 인체 면역 결핍증 비루스 당단백질 gp 160.
  5. 제1항의 제조방법에 의해 정제된 gp 160.
  6. 제2항의 제조방법에 의해 정제된 gp 160.
  7. 제1항의 제조방법에 의해 정제된 gp 160을 함유하며 진단제로서 유효한 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700768A 1988-08-16 1989-08-10 천연 hiv gp 160의 제조방법 KR900702045A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23285988A 1988-08-16 1988-08-16
US232,859 1988-08-16
US07/362,548 US5116740A (en) 1988-08-16 1989-06-07 Method for producing native hiv gp160
US362,548 1989-06-07
PCT/US1989/003428 WO1990002196A1 (en) 1988-08-16 1989-08-10 Method for producing native hiv gp160

Publications (1)

Publication Number Publication Date
KR900702045A true KR900702045A (ko) 1990-12-05

Family

ID=26926401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700768A KR900702045A (ko) 1988-08-16 1989-08-10 천연 hiv gp 160의 제조방법

Country Status (10)

Country Link
US (1) US5116740A (ko)
EP (1) EP0394386B1 (ko)
KR (1) KR900702045A (ko)
AT (1) ATE127526T1 (ko)
AU (1) AU638214B2 (ko)
DE (1) DE68924155T2 (ko)
DK (1) DK175733B1 (ko)
FI (1) FI102684B1 (ko)
HK (1) HK1000969A1 (ko)
WO (1) WO1990002196A1 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254457A (en) * 1989-01-11 1993-10-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies and method for identifying different aids-related viruses
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
JP3494300B2 (ja) * 1990-04-03 2004-02-09 ジェネンテック・インコーポレーテッド Ｈｉｖに対する予防接種のための方法および組成物
AU9028791A (en) * 1990-10-05 1992-04-28 President And Fellows Of Harvard College Detection and isolation of ligands
AU700371B2 (en) 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides
US5736317A (en) * 1995-03-07 1998-04-07 Akzo Nobel N.V. Human T-cell line infected with HIV-2 which secretes a protein corresponding to native HIV-2 gp160 in an extracellular medium
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US20020155120A1 (en) * 1996-07-10 2002-10-24 Lowell George H. Protein and peptide vaccines for inducing mucosal immunity
CN1500806B (zh) * 2002-11-14 2010-05-05 上海科华生物工程股份有限公司 一种HIV－1ɡp160膜蛋白及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699785A (en) * 1984-09-18 1987-10-13 The Regents Of The University Of California Cell line producing feline leukemia virus
AU4310689A (en) * 1988-09-02 1990-04-02 Ohio State University Research Foundation, The Virus-derived antigenic composition and its preparation and use

Also Published As

Publication number Publication date
WO1990002196A1 (en) 1990-03-08
DK175733B1 (da) 2005-02-07
US5116740A (en) 1992-05-26
FI102684B (fi) 1999-01-29
DK90090D0 (da) 1990-04-10
EP0394386B1 (en) 1995-09-06
DE68924155T2 (de) 1996-04-18
FI102684B1 (fi) 1999-01-29
EP0394386A1 (en) 1990-10-31
AU4068789A (en) 1990-03-23
FI901879A0 (fi) 1990-04-12
ATE127526T1 (de) 1995-09-15
HK1000969A1 (en) 1998-05-15
AU638214B2 (en) 1993-06-24
DK90090A (da) 1990-04-10
EP0394386A4 (en) 1991-03-13
DE68924155D1 (de) 1995-10-12

Similar Documents

Publication Publication Date Title
Montagnier et al. Identification and antigenicity of the major envelope glycoprotein of of lymphadenopathy-associated virus
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
GB1521032A (en) Biological treatment
KR860700044A (ko) Aids 관련의 레트로 비루스 (htlv-ⅲ)의 연속생산의 방법 및 그를 위한 셀라인
KR900702045A (ko) 천연 hiv gp 160의 제조방법
EP0272858A3 (en) Recombinant hiv envelope proteins produced in insect cells
ATE7855T1 (de) Herstellung von virusantigenen.
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
EP0731165A3 (en) Human T-cell line infected with HIV-2 which secretes functionally intact HIV-2 GP160
GB8914968D0 (en) Production of virus and purification of viral envelope proteins for vaccine use
SE8701628D0 (sv) Medel for analys mm
US4136168A (en) Process for the preparation of neuraminidase from viral sources and methods of utilizing same
DE3585416D1 (de) Verfahren zur herstellung eines biologischen stoffes.
KR900007436A (ko) 신규의 한탄바이러스 rok 84/105 균주 및 이를 이용한 한탄바이러스 백신의 제조방법
Yahi et al. Production of a highly cytopathic HIV-1 isolate from a human mucosal epithelial cell line cultured on microcarrier beads in serum-free medium
ES8107024A1 (es) Metodo para preparar una vacuna que contiene virus desacti- vado de peritonilis infecciosa felina.
AU1180392A (en) Synthetic peptides suitable to enhance hiv-1 virus infectivity
David-West The use of mouse embryo cell cultures in primary isolation of chikungunya virus
AU4088299A (en) Novel post-transcriptional regulatory elements and uses thereof
KR850001537A (ko) 림포톡신 및 림포톡신- mRNA의 제조방법
Ohtsuki et al. Fine structure of human-and monkey-derived type C virus particles in monkey lymphoid cell lines expressing adult T-cell leukemia-associated antigens
SU1533329A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus, используемый для получения моноклональных антител к белку е оболочки вирусов комплекса клещевого энцефалита
SU1540269A1 (ru) Штамм гибридных культивируемых клеток животного mus musculus, используемый для получения моноклональных антител к поверхностному гликопротеину вирусов комплекса клещевого энцефалита
JPS6485092A (en) Production of protein
Miller Electron microscopic study of Mycoplasma and bovine leukemia virus association in cell culture.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application